Eli Lilly and Company (LLY)
| Market Cap | 861.74B |
| Revenue (ttm) | 35.93B |
| Net Income (ttm) | 6.14B |
| Shares Out | 950.41M |
| EPS (ttm) | 6.79 |
| PE Ratio | 133.54 |
| Forward PE | 60.84 |
| Dividend | $5.20 (0.57%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 4,526,566 |
| Open | 902.71 |
| Previous Close | 914.37 |
| Day's Range | 878.50 - 912.00 |
| 52-Week Range | 434.34 - 916.83 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 806.45 (-11.06%) |
| Earnings Date | Aug 6, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $806.45, which is a decrease of -11.06% from the latest price.
News
Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
Novo Nordisk (NVO) American depositary receipts (ADRs) and Eli Lilly (LLY) shares lost ground Tuesday after U.S. President Joe Biden and Senator Bernie Sanders called out the companies in an op-ed for...
FDA approves Eli Lilly's Alzheimer's drug Kisunla
Eli Lilly's (LLY) Alzheimer's treatment drug Kisunla has gained approval by the US Food and Drug Administration. Yahoo Finance Health Reporter Anjalee Khemlani expands on Kisunla's results in slowing ...
3-Stock Lunch: Eli Lilly, Paypal, & Paramount
Boris Schlossberg, managing director of FX strategy at BK Asset Management, joins CNBC's 'Power Lunch' to discuss how to play three stocks: Eli Lilly, Paypal, and Paramount.
Eli Lilly's Alzheimer's drug wins FDA approval
An Eli Lilly & Co. Alzheimer's drug won Food and Drug Administration approval Tuesday, capping the medication's bumpy ride through the U.S. regulatory process and adding a second new treatment option ...
FDA Approves Eli Lilly's Alzheimer's Drug Donanemab
The Food and Drug Administration on Tuesday approved donanemab for treating Alzheimer's disease, after clinical studies indicated Eli Lilly's drug could significantly slow cognitive decline, following...
FDA approves Eli Lilly Alzheimer's drug, expanding treatment options in the U.S.
The Food and Drug Administration approved Eli Lilly's Alzheimer's drug donanemab, expanding the limited treatment options for the mind-wasting disease. It's a long-awaited win for Eli Lilly after don...
US FDA approves Lilly's Alzheimer's drug
The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the bra...
Approval of Newest Alzheimer's Drug Will Accelerate New Era of Treatment
The approval Tuesday of Eli Lilly's LLY -0.53%decrease; red down pointing triangle new Alzheimer's drug will hasten the transformation of treatment of the dementia-causing condition.
Weighing the Future of Weight Loss Drugs
How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of d...
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices th...
LLY & NVDA: Some of the Best Trends of All Time
Eli Lilly (LLY) and Nvidia (NVDA) are seeing some of the best trends of all time, notes Jerry Parker. He discusses trends to watch in the second half of the year.
Radionetics Oncology Enters Into Strategic Agreement With Lilly
SAN DIEGO--(BUSINESS WIRE)--Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals to treat a bro...
Eli Lilly Soars To 52-Week High: Can The Momentum Continue?
Eli Lilly and Company LLY has hit a new 52-week high, climbing to $915.54 during Friday trading. The stock is up a remarkable 97.38% over the past year and 55.32% year-to-date, fueled by groundbreakin...
India panel urges drug regulator to approve Lilly's obesity drug Mounjaro
An Indian government-approved expert panel has advised the country's drug regulator to approve the import and sale of U.S. drugmaker Eli Lilly's Mounjaro, a blockbuster diabetes drug and a wildly popu...
Super Micro and Nvidia lead the S&P 500 this year. These stocks follow.
This has been a very good year for the stock market as a whole, although the performance of broad U.S. indexes also underscores how important the weighting of an index can be.
Eli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise Chen
Louise Chen, Cantor Fitzgerald analyst, joins CNBC's 'Squawk Box' to discuss Eli Lilly's surge over the past year, manufacturing, and more.
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
Healthy Returns: Eli Lilly, other drugmakers show off encouraging weight loss drug data
Drugmakers showed off data on weight loss and diabetes drugs. Also, Oracle announced the general availability of AI documentation assistant for doctors.
TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DeepBiology--TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases.
Why Drugmaker Eli Lilly Is Partnering With ChatGPT Maker OpenAI
Eli Lilly (LLY) said it is partnering with ChatGPT maker OpenAI to use artificial intelligence (AI) to develop new treatments to combat drug-resistant diseases.
Lilly partners with OpenAI to develop medicines for drug-resistant bacteria
Eli Lilly said on Tuesday it will collaborate with OpenAI to leverage its generative AI to develop antimicrobials that can be used to treat drug-resistant bacteria.
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrob...
From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles
Founded in Indianapolis in 1876, Eli Lilly and Co. (LLY, Financial) is one of the world's top pharmaceutical companies. Its products are manufactured and distributed in more than 100 countries through...
Lilly Declares Third-Quarter 2024 Dividend
INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common ...